Results 271 to 280 of about 371,827 (350)

Antitumor effects of human antithymocyte globulin on peripheral T cell lymphoma via complement-dependent and -independent cytotoxicity in xenograft mouse models. [PDF]

Clin Exp Med
Gao BB, Zhang TQ, Zhang JJ, Wang HN, Huang D, Zhang XH, Kang ZJ, Yang Y, Liu XL, Sun C, Shao J, Yan JS.   +11 more
europepmc   +1 more source

Supplementary Table S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Yuqin Song, Zhengming Jin, Zhiming Li, Yanyan Liu, Lanfang Li, Chuan He, Hang Su, Hui Zhou, Kunyan Li, Siguo Hao, Xuelan Zuo, Jianyuan Wu, Dengju Li, Meng Wu, Xiuhua Sun, Junyuan Qi, Zhen Cai, Zengjun Li, Yijing Li, Yanhua Huang, Jie Shen, Zhenyu Xiao, Jun Zhu   +22 more
openalex   +1 more source

T‐cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Maria L. Andersson, Olina Lind, Kia Heimersson, Anna Berglöf, Teresa del Peso Santos, Lucía Peña‐Pérez, Qing Wang, Tom A. Mulder, Rula Zain, Robert Månsson, Richard Rosenquist, C. I. Edvard Smith, Anders Österborg, Marzia Palma   +13 more
wiley   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Clinical Features and Outcomes of Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified, Treated with CHOP-Based Regimens. [PDF]

Cancers (Basel)
Hu G, Song Z, Lv C, Sun Y, Zhang Y, Liu X, Han X, Li L, Qiu L, Qian Z, Zhou S, Gong W, Meng B, He J, Wang X, Zhang H.   +15 more
europepmc   +1 more source

Precision Oncology for Pediatric Solid Tumors Using In‐Hospital Pediatric/AYA Malignancy‐Specific Panel Sequencing

Cancer Science, EarlyView.
Our findings indicate that a pediatric/AYA‐specific targeted panel deployed in a hospital can deliver rapid, clinically actionable molecular insights with high diagnostic and prognostic yield. This complements larger sequencing platforms by offering speed, focused content, and easier interpretation.
Masato Kojima, Sho Kurihara, Isamu Saeki, Ryo Touge, Keigo Nakashima, Shuhei Karakawa, Fumiyuki Yamasaki, Satoshi Okada, Eiso Hiyama   +8 more
wiley   +1 more source

CMOEP regimen in the treatment of untreated peripheral T-cell lymphoma: a multicenter, single-arm, phase I study. [PDF]

Front Immunol
Yu J, Sun X, Gao G, Yu L, Wang J, Qiu L, Qian Z, Li W, Zhang H.   +8 more
europepmc   +1 more source

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

Cancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao, Xiaodan Wang, Chun‐Hui Jin, Zhifeng Wei, Qinghao Ding, Ke‐Ke Zhang, Bo‐Wen Dong, Kai‐Wen Zheng, Yufei Hou, Tao Zhang, Wen‐Jie Zhao, Zheng Hu, Yong‐Guang Yang   +12 more
wiley   +1 more source

Epstein-barr virus-encoded small RNA incorporated prognostic model enables precision risk stratification and guides treatment decisions in peripheral t-cell lymphoma: a multicenter retrospective cohort. [PDF]

Ann Hematol
Chen ZT, Huang L, Guo HG, Lin CD, Jiang XM, Wei XJ, Chen FL, Liu SC, Zhang H, Liang ZL, Wang N, Zhang XD, Lin LE, Liu TB, Zhou JH, Peng ZG, Li WY.   +16 more
europepmc   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source